Analyst Opinion on Eli Lilly & Co. and Pfizer Inc. -- Drug Manufacturers Countering Patent Expirations with New Products

(firmenpresse) - LONDON -- (Marketwire) -- 10/29/12 -- The drug manufacturers - major industry, which includes players such as Eli Lilly & Co. and Pfizer Inc., has been facing challenging times of late. Patent expirations continue to put dents in revenue and earnings and with more expiration upcoming, it is essential for companies to bring new products to the market.

is unswerving when it comes teaching the new and pro traders on how to take the helm in a market environment that has been seeing waves upon waves of changes and reap the rewards of participating in various sectors. We invite serious traders to join our financial community so that they can benefit from our free analytical coverage on (NYSE: LLY) and (NYSE: PFE) by signing up at



Pfizer has been performing well over the last little while, and recently announced that the European Commission has granted it conditional marketing authorization in the EU for XALKORI® for the treatment of adults with previously treated anaplastic lymphoma kinase-positive advanced non-small cell lung cancer. This is positive news for the company as well as patients. See what our analysts have to say on Pfizer Inc. Follow the Link below



While Eli Lilly has been developing a strong pipeline of potential products, its recent quarterly results have been impacted by patent expirations. In its 3rd quarter that company posted an 11% decline in worldwide revenue, in part due to Zyprexa patent expirations. Revenue from its Cymbalta offering improved significantly. However, adjusted earnings per share contracted when compared to the same period last year. Analyst opinion on Eli Lilly & Co. accessible for free at



Walls Street Active offers topmost independent research and investment strategies with the sole purpose of consistently identifying stocks that provide the biggest return on investment for our subscribers. We provide sharp North American stock investing opinion with a truly outstanding success rate. Our goal is for likeminded traders to make a lot of money through our information.

Read our

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 29.10.2012 - 14:17 Uhr
Sprache: Deutsch
News-ID 197179
Anzahl Zeichen: 0

contact information:
Town:

LONDON

Kategorie:

Commercial & Investment Banking

Diese Pressemitteilung wurde bisher 217 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Analyst Opinion on Eli Lilly & Co. and Pfizer Inc. -- Drug Manufacturers Countering Patent Expirations with New Products"
steht unter der journalistisch-redaktionellen Verantwortung von

WallStreetActive.Com (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

ABC, MCK, IP and ADT Freshly Hit a New 52-Week High ...

LONDON -- (Marketwire) -- 12/17/12 -- Wall Street Active pro-traders will be assisting investors today on ABC, MCK, IP and ADT, and provide insight based on their extensive experience so that you can boost your stock portfolio on the short-term or t ...

Analyst Call for WMT, NOK, SD and WFC Provided by WallStreetActive.com ...

LONDON -- (Marketwire) -- 12/04/12 -- Wall Street Active analysts will be speaking to investors today about four companies mentioned in this release. As a leading provider of free in-depth reports and timely market updates, investors are lucky today ...

Analyst Call for GOOG, NWSA, DAL and AMZN Provided by WallStreetActive.com ...

LONDON -- (Marketwire) -- 12/04/12 -- Wall Street Active analysts will be speaking to investors today about four companies mentioned in this release. As a leading provider of free in depth reports and timely market updates, investors are lucky today ...

Alle Meldungen von WallStreetActive.Com